Muscular dystrophies are primary diseases of muscle due to mutations in more than 40 genes, which result in dystrophic changes on muscle biopsy. Now that most of the genes responsible for these ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and ...

Potential Positives. Quantum BioPharma signed an agreement with a global pharmaceutical contract research organization to prepare an IND application for Lucid-21-302, moving closer to initiating a ...

Also making notable jumps were No. 6 Regeneron, from 15th place, No. 7 UCB, which vaulted from outside of the top 20, and No. 10 Novartis, which was up from 17th place.

Sanofi picks up Blueprint in deal worth up to $9.5 billion, in rare immunological disease expansion Heerea Rikhraj June 9, 2025 ; Opioid settlement windfall: Where the billions are going Aneri Pattani ...

Title: Federal policy changes spell turmoil for biopharma. Author: * Send Email To: Enter the valid email address. * Add Comment To Email: Enter the comment.

Former POINT Biopharma CEO Joe McCann joins TAG1 to strengthen Lead-212 supply for TATs. McCann, who previously served as CEO of POINT Biopharma and has led multiple companies through growth, clinical ...

But, like companies in many other industries, although biopharma leaders and personnel may be psychologically ready to accept AI, they aren’t necessarily prepared for that integration ...

Adopting a platform approach to designing new therapies will speed the delivery of innovative genomic treatments to patients—but only if developers, regulators, and manufacturers work together to ...

As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards? That’s what the European ...

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market. The healthcare ecosystem has undergone a ...